Toronto, Ontario, November 13, 2020 – NeuPath Health Inc. (TSX-V:NPTH) (“NeuPath” or the “Company”), Canada’s largest provider of chronic pain management services, is pleased to announce the closing of its previously announced bought deal public offering (the “Offering”) pursuant to an underwriting agreement (the “Underwriting Agreement”) dated October 23, 2020 between Stifel GMP as co-lead underwriter and sole bookrunner, and INFOR Financial Inc. as co-lead underwriter of a syndicate of underwriters that also included Haywood Securities Inc. (collectively, the “Underwriters”), and the Company.

The Company sold 13,340,000 units (“Units”) of the Company in the Offering, including the full exercise by the Underwriters of their option to purchase up to an additional 1,740,000 Units, for aggregate gross proceeds of $12,006,000, before deducting underwriting commissions and other offering expenses. Each Unit was issued at a price of $0.90 per Unit and is comprised of one common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a “Warrant”).

Please click here to see the full PDF Press Release.